NCT06664814View on ClinicalTrials.gov

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 28, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

December 1, 2027

Conditions

Focal Segmental Glomerulosclerosis

Interventions

DRUG

ManNAc

2 grams twice daily by mouth

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Human Genome Research Institute (NHGRI)

NIH

NCT06664814 - An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis | Biotech Hunter | Biotech Hunter